GleamWall
中文EN

PCSA Processa Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1533743 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-1,393.5%
TTM EPS YoY34.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-203.8%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets1.0%
Debt / equity—
Current ratio97.70x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.07x
Accruals ratio-189.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue———$0$0
R&D expense$7.81M$7.27M$5.80M$11.49M$6.88M
SG&A expense$6.18M$4.78M$5.66M$8.76M$4.69M
Operating income-$13.99M-$12.05M-$11.46M-$27.53M-$12.13M
Interest expense————$362
Pretax income-$13.56M-$11.85M-$11.12M-$27.42M-$11.96M
Income tax————-$530,611
Net income-$13.56M-$11.85M-$11.12M-$27.42M-$11.43M
EBITDA-$13.99M-$12.05M-$11.46M—-$12.13M
EPS (basic)-10.36-96.78-8.48-34.05-0.75
EPS (diluted)-10.36-96.78-8.48-34.05-0.75
Weighted avg. shares (diluted)1.31M122,4381.31M805,47715.32M
Balance sheet
Cash & equivalents$5.54M$1.19M$4.71M$6.50M$16.50M
Current assets$5.67M$1.88M$5.63M$8.39M$18.33M
PP&E, net$4,000$5,016$2,554——
Intangibles————$8.06M
Total assets$7.81M$3.23M$5.79M$8.62M$26.46M
Current liabilities$2.24M$1.53M$730,579$998,556$971,020
Total liabilities$2.24M$1.53M$797,484$1.15M$978,405
Shareholders' equity$5.58M$1.70M$4.99M$7.47M$25.49M
Shares outstanding2.57M148,1081.29M801,77415.71M
Cash flow statement
Operating cash flow-$11.39M-$11.25M-$8.06M-$9.61M-$8.72M
Capital expenditure—$3,244$2,776——
Free cash flow—-$11.25M-$8.07M——
Investing cash flow-$850,000-$3,244-$2,776——
Financing cash flow$16.58M$7.73M$6.27M-$388,843$9.80M
Depreciation & amortization$1,204$782$222—$484
Stock-based compensation$857,550$629,514$1.06M$8.83M$3.41M

Free plan shows the latest 5 periods; Pro shows all 14 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-19 06:28.